Washed microbiota transplantation promotes homing of group 3 innate lymphoid cells to the liver via the CXCL16/CXCR6 axis: a potential treatment for metabolic-associated fatty liver disease

References

• Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, Yong JN, Xiao J, Lee CW, Chan M, et al. An observational data meta-analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2023;21(3):619–629.e7. doi:10.1016/j.cgh.2021.11.038.
   PubMed Web of Science ®Google Scholar
• Shiha G, Korenjak M, Eskridge W, Casanovas T, Velez-Moller P, Hogstrom S, Richardson B, Munoz C, Sigurethardottir S, Coulibaly A, et al. Redefining fatty liver disease: an international patient perspective. Lancet Gastroenterol Hepatol. 2021;6(1):73–22. doi:10.1016/S2468-1253(20)30294-6.
   PubMed Web of Science ®Google Scholar
• McPherson S, Armstrong MJ, Cobbold JF, Corless L, Anstee QM, Aspinall RJ, Barclay ST, Brennan PN, Cacciottolo TM, Goldin RD, et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol. 2022;7(8):755–769. doi:10.1016/S2468-1253(22)00061-9.
   PubMed Web of Science ®Google Scholar
• Wong VW, Ekstedt M, Wong GL, Hagstrom H. Changing epidemiology, global trends and implications for outcomes of NAFLD. J Hepatol. 2023;79(3):842–852. doi:10.1016/j.jhep.2023.04.036.
   PubMed Web of Science ®Google Scholar
• Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023;8(10):943–954. doi:10.1016/S2468-1253(23)00159-0.
   PubMed Web of Science ®Google Scholar
• Hsu CL, Schnabl B. The gut-liver axis and gut microbiota in health and liver disease. Nat Rev Microbiol. 2023;21(11):719–733. doi:10.1038/s41579-023-00904-3.
   PubMed Web of Science ®Google Scholar
• Yang C, Xu J, Xu X, Xu W, Tong B, Wang S, Ji R, Tan Y, Zhu Y. Characteristics of gut microbiota in patients with metabolic associated fatty liver disease. Sci Rep. 2023;13(1):9988. doi:10.1038/s41598-023-37163-4.
   PubMed Web of Science ®Google Scholar
• Oh JH, Lee JH, Cho MS, Kim H, Chun J, Lee JH, Yoon Y, Kang W. Characterization of gut microbiome in Korean patients with metabolic associated fatty liver disease. Nutrients. 2021;13(3):1013. doi:10.3390/nu13031013.
   PubMed Web of Science ®Google Scholar
• Shu Y, Huang Y, Dong W, Fan X, Sun Y, Chen G, Zeng X, Ye H. The polysaccharides from Auricularia auricula alleviate non-alcoholic fatty liver disease via modulating gut microbiota and bile acids metabolism. Int J Biol Macromol. 2023;246:125662. doi:10.1016/j.ijbiomac.2023.125662.
   PubMed Web of Science ®Google Scholar
• Song Q, Zhang X, Liu W, Wei H, Liang W, Zhou Y, Ding Y, Ji F, Ho-Kwan Cheung A, Wong N, et al. Bifidobacterium pseudolongum-generated acetate suppresses non-alcoholic fatty liver disease-associated hepatocellular carcinoma. J Hepatol. 2023;79(6):1352–1365. doi:10.1016/j.jhep.2023.07.005.
   PubMed Web of Science ®Google Scholar
• Yao F, Jia R, Huang H, Yu Y, Mei L, Bai L, Ding Y, Zheng P. Effect of Lactobacillus paracasei N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. Arch Med Sci. 2019;15(5):1336–1344. doi:10.5114/aoms.2019.86611.
   PubMed Web of Science ®Google Scholar
• Mohamad nor MH, Ayob N, Mokhtar NM, Raja Ali RA, Tan GC, Wong Z, Shafiee NH, Wong YP, Mustangin M, Nawawi KNM. The effect of probiotics (MCP((R)) BCMC((R)) Strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease. Nutrients. 2021;13(9):3192. doi:10.3390/nu13093192.
   PubMed Web of Science ®Google Scholar
• Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, et al. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020;158(6):1597–1610 e1597. doi:10.1053/j.gastro.2020.01.031.
   PubMed Web of Science ®Google Scholar
• Porcari S, Benech N, Valles-Colomer M, Segata N, Gasbarrini A, Cammarota G, Sokol H, Ianiro G. Key determinants of success in fecal microbiota transplantation: from microbiome to clinic. Cell Host & Microbe. 2023;31(5):712–733. doi:10.1016/j.chom.2023.03.020.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang S, Borody TJ, Zhang F. Encyclopedia of fecal microbiota transplantation: a review of effectiveness in the treatment of 85 diseases. Chin Med J (Engl). 2022;135(16):1927–1939. doi:10.1097/CM9.0000000000002339.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lu G, Zhao Z, Liu Y, Shen Q, Li P, Chen Y, Yin H, Wang H, Marcella C, et al. Washed microbiota transplantation vs. manual fecal microbiota transplantation: clinical findings, animal studies and in vitro screening. Protein Cell. 2020;11(4):251–266. doi:10.1007/s13238-019-00684-8.
   PubMed Web of Science ®Google Scholar
• Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates high-fat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017;7(1):1529. doi:10.1038/s41598-017-01751-y.
   PubMed Web of Science ®Google Scholar
• Chun E, Lavoie S, Fonseca-Pereira D, Bae S, Michaud M, Hoveyda HR, Fraser GL, Gallini Comeau CA, Glickman JN, Fuller MH, et al. Metabolite-sensing receptor Ffar2 regulates colonic group 3 innate lymphoid cells and gut immunity. Immunity. 2019;51(5):871–884 e876. doi:10.1016/j.immuni.2019.09.014.
   PubMed Web of Science ®Google Scholar
• Liu Y, Song Y, Lin D, Lei L, Mei Y, Jin Z, Gong H, Zhu Y, Hu B, Zhang Y, et al. NCR(-) group 3 innate lymphoid cells orchestrate IL-23/IL-17 axis to promote hepatocellular carcinoma development. EBioMedicine. 2019;41:333–344. doi:10.1016/j.ebiom.2019.02.050.
   PubMed Web of Science ®Google Scholar
• Eggenhofer E, Sabet-Rashedi M, Lantow M, Renner P, Rovira J, Koehl GE, Schlitt HJ, Geissler EK, Kroemer A. RORgammat(+) IL-22-producing NKp46(+) cells protect from hepatic ischemia reperfusion injury in mice. J Hepatol. 2016;64(1):128–134. doi:10.1016/j.jhep.2015.08.023.
   PubMed Web of Science ®Google Scholar
• Wang S, Li J, Wu S, Cheng L, Shen Y, Ma W, She W, Yang C, Wang J, Jiang W. Type 3 innate lymphoid cell: a new player in liver fibrosis progression. Clin Sci (Lond). 2018;132(24):2565–2582. doi:10.1042/CS20180482.
   PubMed Web of Science ®Google Scholar
• Spindelboeck W, Halwachs B, Bayer N, Huber-Krassnitzer B, Schulz E, Uhl B, Gaksch L, Hatzl S, Bachmayr V, Kleissl L, et al. Antibiotic use and ileocolonic immune cells in patients receiving fecal microbiota transplantation for refractory intestinal GvHD: a prospective cohort study. Ther Adv Hematol. 2021;12:20406207211058333. doi:10.1177/20406207211058333.
   Web of Science ®Google Scholar
• Su L, Wu Z, Chi Y, Song Y, Xu J, Tan J, Cong X, Liu Y. Mesenteric lymph node CD4(+) T lymphocytes migrate to liver and contribute to non-alcoholic fatty liver disease. Cell Immunol. 2019;337:33–41. doi:10.1016/j.cellimm.2019.01.005.
   PubMed Web of Science ®Google Scholar
• Hu C, Xu B, Wang X, Wan WH, Lu J, Kong D, Jin Y, You W, Sun H, Mu X, et al. Gut microbiota-derived short-chain fatty acids regulate group 3 innate lymphoid cells in HCC. Hepatology. 2023;77(1):48–64. doi:10.1002/hep.32449.
   PubMed Web of Science ®Google Scholar
• Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, et al. Innate lymphoid cells: 10 years on. Cell. 2018;174(5):1054–1066. doi:10.1016/j.cell.2018.07.017.
   PubMed Web of Science ®Google Scholar
• Huang Y, Mao K, Chen X, Sun MA, Kawabe T, Li W, Usher N, Zhu J, Urban JF Jr, Paul WE, et al. S1P-dependent interorgan trafficking of group 2 innate lymphoid cells supports host defense. Science. 2018;359(6371):114–119. doi:10.1126/science.aam5809.
   PubMed Web of Science ®Google Scholar
• Hunter S, Willcox CR, Davey MS, Kasatskaya SA, Jeffery HC, Chudakov DM, Oo YH, Willcox BE. Human liver infiltrating gammadelta T cells are composed of clonally expanded circulating and tissue-resident populations. J Hepatol. 2018;69(3):654–665. doi:10.1016/j.jhep.2018.05.007.
   PubMed Web of Science ®Google Scholar
• de Krijger M, Wildenberg ME, de Jonge WJ, Ponsioen CY. Return to sender: lymphocyte trafficking mechanisms as contributors to primary sclerosing cholangitis. J Hepatol. 2019;71(3):603–615. doi:10.1016/j.jhep.2019.05.006.
   PubMed Web of Science ®Google Scholar
• Zhou L, Chu C, Teng F, Bessman NJ, Goc J, Santosa EK, Putzel GG, Kabata H, Kelsen JR, Baldassano RN, et al. Innate lymphoid cells support regulatory T cells in the intestine through interleukin-2. Nature. 2019;568(7752):405–409. doi:10.1038/s41586-019-1082-x.
   PubMed Web of Science ®Google Scholar
• Craven L, Rahman A, Nair Parvathy S, Beaton M, Silverman J, Qumosani K, Hramiak I, Hegele R, Joy T, Meddings J, et al. Allogenic fecal microbiota transplantation in patients with nonalcoholic fatty liver disease improves abnormal small intestinal permeability: a randomized control trial. Am J Gastroenterol. 2020;115(7):1055–1065. doi:10.14309/ajg.0000000000000661.
   PubMed Web of Science ®Google Scholar
• Xue L, Deng Z, Luo W, He X, Chen Y. Effect of fecal microbiota transplantation on non-alcoholic fatty liver disease: a randomized clinical trial. Front Cell Infect Microbiol. 2022;12:759306. doi:10.3389/fcimb.2022.759306.
   PubMed Web of Science ®Google Scholar
• Stols-Goncalves D, Mak AL, Madsen MS, van der Vossen EWJ, Bruinstroop E, Henneman P, Mol F, Scheithauer TPM, Smits L, Witjes J, et al. Faecal Microbiota transplantation affects liver DNA methylation in Non-alcoholic fatty liver disease: a multi-omics approach. Gut Microbes. 2023;15(1):2223330. doi:10.1080/19490976.2023.2223330.
   PubMed Web of Science ®Google Scholar
• Chen ZX, Liu HQ, Wu ZH, He JL, Zhong HJ. Type 3 innate lymphoid cells as an indicator of renal dysfunction and serum uric acid in hyperuricemia. Adv Clin Exp Med. 2023;32(3):307–313. doi:10.17219/acem/154625.
   PubMed Web of Science ®Google Scholar
• Zhuang YP, Pan ZY, Huang JM, Zhou HG, Yang XR, Zhong HJ. Negative correlation between circulating integrin alpha4(+) group 3 innate lymphoid cells and the severity of type 2 diabetes. Int Immunopharmacol. 2023;119:110237. doi:10.1016/j.intimp.2023.110237.
   PubMed Web of Science ®Google Scholar
• Gasteiger G, Fan X, Dikiy S, Lee SY, Rudensky AY. Tissue residency of innate lymphoid cells in lymphoid and nonlymphoid organs. Science. 2015;350(6263):981–985. doi:10.1126/science.aac9593.
   PubMed Web of Science ®Google Scholar
• van Hoeven V, Munneke JM, Cornelissen AS, Omar SZ, Spruit MJ, Kleijer M, Bernink JH, Blom B, Voermans C, Hazenberg MD. Mesenchymal stromal cells stimulate the proliferation and IL-22 production of group 3 innate lymphoid cells. J Immunol. 2018;201(4):1165–1173. doi:10.4049/jimmunol.1700901.
   PubMed Web of Science ®Google Scholar
• Simoni Y, Fehlings M, Kloverpris HN, McGovern N, Koo SL, Loh CY, Lim S, Kurioka A, Fergusson JR, Tang CL, et al. Human innate lymphoid cell subsets possess tissue-type based heterogeneity in phenotype and frequency. Immunity. 2017;46(1):148–161. doi:10.1016/j.immuni.2016.11.005.
   PubMed Web of Science ®Google Scholar
• Sonnenberg GF, Hepworth MR. Functional interactions between innate lymphoid cells and adaptive immunity. Nat Rev Immunol. 2019;19(10):599–613. doi:10.1038/s41577-019-0194-8.
   PubMed Web of Science ®Google Scholar
• Li F, Liang Z, Zhong H, Hu X, Tang Z, Zhu C, Shen J, Han X, Lin R, Zheng R, et al. Group 3 innate lymphoid cells exacerbate lupus nephritis by promoting B cell activation in kidney ectopic lymphoid structures. Adv Sci (Weinh). 2023;10(35):e2302804. doi:10.1002/advs.202302804.
   PubMedGoogle Scholar
• Tiberio L, Del Prete A, Schioppa T, Sozio F, Bosisio D, Sozzani S. Chemokine and chemotactic signals in dendritic cell migration. Cell Mol Immunol. 2018;15(4):346–352. doi:10.1038/s41423-018-0005-3.
   PubMed Web of Science ®Google Scholar
• Robinette ML, Fuchs A, Cortez VS, Lee JS, Wang Y, Durum SK, Gilfillan S, Colonna M, Immunological Genome C. Transcriptional programs define molecular characteristics of innate lymphoid cell classes and subsets. Nat Immunol. 2015;16(3):306–317. doi:10.1038/ni.3094.
   PubMed Web of Science ®Google Scholar
• Willinger T. Metabolic control of innate lymphoid cell migration. Front Immunol. 2019;10:2010. doi:10.3389/fimmu.2019.02010.
   PubMed Web of Science ®Google Scholar
• Spits H, Bernink JH, Lanier L. NK cells and type 1 innate lymphoid cells: partners in host defense. Nat Immunol. 2016;17(7):758–764. doi:10.1038/ni.3482.
   PubMed Web of Science ®Google Scholar
• Hamaguchi M, Okamura T, Fukuda T, Nishida K, Yoshimura Y, Hashimoto Y, Ushigome E, Nakanishi N, Majima S, Asano M, et al. Group 3 innate lymphoid cells protect steatohepatitis from high-fat diet induced toxicity. Front Immunol. 2021;12:648754. doi:10.3389/fimmu.2021.648754.
   PubMed Web of Science ®Google Scholar
• Satoh-Takayama N, Serafini N, Verrier T, Rekiki A, Renauld JC, Frankel G, Di Santo JP. The chemokine receptor CXCR6 controls the functional topography of interleukin-22 producing intestinal innate lymphoid cells. Immunity. 2014;41(5):776–788. doi:10.1016/j.immuni.2014.10.007.
   PubMed Web of Science ®Google Scholar
• Zai W, Chen W, Liu H, Ju D. Therapeutic opportunities of IL-22 in non-alcoholic fatty liver disease: from molecular mechanisms to clinical applications. Biomedicines. 2021;9(12):1912. doi:10.3390/biomedicines9121912.
   PubMed Web of Science ®Google Scholar
• Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. J Hepatol. 2020;73(1):202–209. doi:10.1016/j.jhep.2020.03.039.
   PubMed Web of Science ®Google Scholar
• Zhong HJ, Chen WR, Lu XJ, Hu DX, Lin DJ, Liu T, Wu L, Wu LH, He XX. Washed microbiota transplantation improves haemoglobin levels in anaemia of chronic disease. Eur J Clin Invest. 2023;53(12):e14072. doi:10.1111/eci.14072.
   PubMed Web of Science ®Google Scholar
• Tong J, Li D, Meng H, Sun D, Lan X, Ni M, Ma J, Zeng F, Sun S, Fu J, et al. Targeting a novel inducible GPX4 alternative isoform to alleviate ferroptosis and treat metabolic-associated fatty liver disease. Acta Pharm Sin B. 2022;12(9):3650–3666. doi:10.1016/j.apsb.2022.02.003.
   PubMed Web of Science ®Google Scholar
• Rakoff-Nahoum S, Paglino J, Eslami-Varzaneh F, Edberg S, Medzhitov R. Recognition of commensal microflora by toll-like receptors is required for intestinal homeostasis. Cell. 2004;118(2):229–241. doi:10.1016/j.cell.2004.07.002.
   PubMed Web of Science ®Google Scholar
• Hou YF, Shan C, Zhuang SY, Zhuang QQ, Ghosh A, Zhu KC, Kong XK, Wang SM, Gong YL, Yang YY, et al. Gut microbiota-derived propionate mediates the neuroprotective effect of osteocalcin in a mouse model of Parkinson’s disease. Microbiome. 2021;9(1):34. doi:10.1186/s40168-020-00988-6.
   PubMed Web of Science ®Google Scholar
• Zhong HJ, Zeng HL, Cai YL, Zhuang YP, Liou YL, Wu Q, He XX. Washed microbiota transplantation lowers blood pressure in patients with hypertension. Front Cell Infect Microbiol. 2021;11:679624. doi:10.3389/fcimb.2021.679624.
   PubMed Web of Science ®Google Scholar
• Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27(21):2957–2963. doi:10.1093/bioinformatics/btr507.
   PubMed Web of Science ®Google Scholar
• Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884–i890. doi:10.1093/bioinformatics/bty560.
   PubMed Web of Science ®Google Scholar
• Callahan BJ, McMurdie PJ, Rosen MJ, Han AW, Johnson AJ, Holmes SP. DADA2: High-resolution sample inference from Illumina amplicon data. Nat Methods. 2016;13(7):581–583. doi:10.1038/nmeth.3869.
   PubMed Web of Science ®Google Scholar
• Bolyen E, Rideout JR, Dillon MR, Bokulich NA, Abnet CC, Al-Ghalith GA, Alexander H, Alm EJ, Arumugam M, Asnicar F, et al. Reproducible, interactive, scalable and extensible microbiome data science using QIIME 2. Nat Biotechnol. 2019;37(8):852–857. doi:10.1038/s41587-019-0209-9.
   PubMed Web of Science ®Google Scholar
• Kim D, Langmead B, Salzberg SL. HISAT: a fast spliced aligner with low memory requirements. Nat Methods. 2015;12(4):357–360. doi:10.1038/nmeth.3317.
   PubMed Web of Science ®Google Scholar
• Pertea M, Pertea GM, Antonescu CM, Chang TC, Mendell JT, Salzberg SL. StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nat Biotechnol. 2015;33(3):290–295. doi:10.1038/nbt.3122.
   PubMed Web of Science ®Google Scholar
• Li B, Dewey CN. RSEM: accurate transcript quantification from RNA-Seq data with or without a reference genome. BMC Bioinf. 2011;12(1):323. doi:10.1186/1471-2105-12-323.
   PubMed Web of Science ®Google Scholar
• Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41(6):1313–1321. doi:10.1002/hep.20701.
   PubMed Web of Science ®Google Scholar